The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Ajinomoto Obtains Domestic Rights to IBD Treatment from Dr Falk
April 18, 2011
- NEW PRODUCTS
April 18, 2011
- FDA Approves HCC Test System μTASWako i30: Wako Pure Chemical
April 18, 2011
- BioWa Licenses Potelligent to OBT
April 18, 2011
- Takeda, Heptares of UK Announce 2-Year Research Collaboration
April 18, 2011
- Eisai's Subsidiary Morphotek Acquires Tumor Targeting Assets from TransMolecular
April 18, 2011
- Sanofi-aventis Acquires Additional Nichi-Iko Shares
April 18, 2011
- BI 201335 NA Shows Favorable Results for Hepatitis C in PIIb: BI
April 18, 2011
- Disaster to Have No Long-term Impact on Japan Business: Chairman Barner of BI
April 18, 2011
- Hisamitsu: Acquisition of Noven Contributes to Growth in Sales
April 18, 2011
- Council Beefs Up Activities to Improve Environment for Drug Discovery in Osaka
April 18, 2011
- Operating, Net Losses Decrease: MediciNova
April 18, 2011
- Motesanib Fails to Increase OS in Non-SCC NSCLC in PIII
April 18, 2011
- EPS to Establish Wholly Owned Subsidiary in South Korea
April 18, 2011
- APA Elevates Gastric pH in PI Trial: RaQualia
April 18, 2011
- Quintiles to Expand Tokyo Laboratory
April 18, 2011
- Olmesartan + CCB Suppress CV Events in Hypertensive Patients with a History of CV Disease
April 18, 2011
- Baxter Announces Change in Storage Temperature for Advate
April 18, 2011
- Valsartan, CCB Show Similar CV Events
April 18, 2011
- JP 16th Edition Published with 106 More Drugs Added
April 18, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…